LGA
BLCM

Lebenthal Global Advisors’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Lebenthal Global Advisors’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-30
Closed – – 576
2020
Q4 		$0 Buy
+30
New +$127 ﹤0.01% 583

Other funds holding BLCM

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Lebenthal Global Advisors's BLCM Position: Q1 2021 in Review

Lebenthal Global Advisors sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2021, closing a stake of 30 shares.

Lebenthal Global Advisors first reported a position in BLCM in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 29 funds tracked by Wall St. Rank hold BLCM as of Q1 2021.

  • Lebenthal Global Advisors reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • Lebenthal Global Advisors sold 30 Bellicum Pharmaceuticals, Inc. shares in Q1 2021.
  • Lebenthal Global Advisors first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2020 and held it in 1 quarter.
  • Lebenthal Global Advisors's Bellicum Pharmaceuticals, Inc. position peaked at $0 in Q4 2020.
  • 29 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2021.

Based on Lebenthal Global Advisors's 13F filing for Q1 2021, filed 7 May 2021.